When a Food and Drug Administration advisory panel meets Monday to size up an Eli Lilly experimental Alzheimer’s drug, questions about safety, selection of patients for treatment, and dosing will be at the fore, documents released Thursday show.
Article Attribution | Read More at Article Source
[mwai_chat context=”Let’s have a discussion about this article:nnWhen a Food and Drug Administration advisory panel meets Monday to size up an Eli Lilly experimental Alzheimer’s drug, questions about safety, selection of patients for treatment, and dosing will be at the fore, documents released Thursday show.nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]